CARL
Get informed when a big investor buys or sells
+ Follow| Market cap | $293.60 Million |
|---|---|
| Enterprise Value | $237.84 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.12 |
| Beta | 2.02 |
| Outstanding Shares | 26,835,841 |
| P/E Ratio | -4.43 |
|---|---|
| PEG | -8.55 |
| Price to Sales | 5.73 |
| Price to Book Ratio | 3.82 |
| Enterprise Value to Revenue | 4.21 |
| Enterprise Value to EBIT | -6.25 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.19 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 19.76%▼ 13.11% |
|---|---|
| Total Invested | $48.00M▼ 16.83% |
| Investors Holding | 66▲ 9.00% |
No data
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. Its product ...